Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

The prognosis for myelodysplastic syndromes (MDS) patients who fail to respond or become resistant to hypomethylating agents (HMA) is dismal, and there is a compelling unmet medical need for novel ...